US Markets
AZN

AstraZeneca's lung disease treatment gets FDA nod

Credit: REUTERS/Brendan McDermid

The U.S. Food and Drug Administration approved AstraZeneca's drug to treat patients with a form of lung disease, the drugmaker said on Friday.

July 24 (Reuters) - The U.S. Food and Drug Administration approved AstraZeneca's drug to treat patients with a form of lung disease, the drugmaker said on Friday.

The drug Breztri Aerosphere is being approved as a maintenance treatment for patients with chronic obstructive pulmonary disease (COPD), the third leading cause of death globally, the British drugmaker said. (Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Shounak Dasgupta) ((Aakash.B@thomsonreuters.com; within the U.S. +16462238780, outside the U.S. +91 80 67491576; Twitter: @JagadeeshAakash;)) Keywords: ASTRAZENECA FDA/ (URGENT)

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AZN

Latest Markets Videos

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More